Tissue Repository for Studies of Myasthenia Gravis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02902536

Enrollment

Registered

2016-09-15

Start date

2015-08-31

Completion date

2019-08-31

Last updated

2019-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis

Keywords

Myasthenia Gravis

Brief summary

This is a study during which the investigators collect plasma and cells from patients with myasthenia gravis for the purpose of finding new antibodies.

Detailed description

This is a bio-specimen collection study. The investigators will collect plasma and peripheral lymphocytes. Plasma will be collected either when the patient undergoes plasma exchange, a decision independent of this study, or through a scheduled blood draw. Patient plasma will be screened for novel antibodies which may cause myasthenia gravis. Subjects that are found to be positive for candidate antigens for myasthenia gravis will have a clinical evaluation which will consist of several disease rating scales will be performed (QMG score, MG-composite, Myasthenia Gravis Foundation of America (MGFA) clinical classification, MG-Quality of Life (QOL)15, MGFA Therapy Status).

Interventions

OTHERNo interventions

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* 18 years of age or older. * Clinical Diagnosis of MG with supporting evidence either from antibody testing, repetitive nerve stimulations study (RNS) or Single Fiber Electromyography (EMG) (SFEMG).

Exclusion criteria

* Significant medical condition that would make participation in diagnostic and research part of evaluation impossible or risky. Acute or unstable medical condition. * Inability to provide informed consent, either directly or via appointed power of attorney. * Unwillingness to consent for collection of biological samples or their cryopreservation. * Unable to provide evidence of previous antibody testing or neurophysiology confirming the diagnosis of Myasthenia Gravis. * Any bleeding disorder that would prevent or present any danger during blood extraction.

Design outcomes

Primary

Measure	Time frame
Identification of New Antibodies in Myasthenia Gravis assessed by enzyme-linked immunosorbent assay (ELISA)	Up to 2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026